A drug used to treat stage III non-small cell lung cancer (NSCLC) that cannot be removed by surgery. It is used in patients whose disease did not get worse after treatment with radiation therapy and anticancer drugs that included platinum. Durvalumab is also used to treat urothelial carcinoma (a type of bladder cancer) that is advanced or has spread to other parts of the body. It is used in patients whose disease got worse during or after treatment with anticancer drugs that included platinum. It is also being studied in the treatment of other types of cancer. Durvalumab binds to a protein called PD-L1, which is found on some cancer cells. Durvalumab may block this protein and help the immune system kill cancer cells. It is a type of monoclonal antibody and a type of immune checkpoint inhibitor. Also called Imfinzi.